Browse News
Filter News
Found 11 articles
-
Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones
6/2/2023
Terran Biosciences, Inc. has entered into an agreement with French pharmaceutical company Pierre Fabre Médicament S.A.S for worldwide exclusive rights to develop and commercialize a pipeline of Pierre Fabre's assets to treat neuropsychiatric illnesses.
-
Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA
5/19/2023
Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering what may be the first new salts, co-crystals, and polymorphs of psilocybin in history.
-
Terran Biosciences announces publication of four PCT patent applications covering breakthroughs in novel empathogens, including improved versions of methylone, ethylone, MDEA, MDAI, and MBDB
5/11/2023
Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of four PCT patent applications covering novel improvements to the empathogens methylone (also known as bk-MDMA or MDMC), ethylone, MDEA (also known as MDE), MDAI, and MBDB.
-
Terran Biosciences announces publication of PCT patent application covering novel orally active forms of psilocin with improved pharmacokinetic properties
2/24/2023
Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering novel prodrugs of psilocin.
-
Terran Biosciences announces publication of PCT patent applications covering orally active forms of DMT and 5-MeO-DMT and long-acting MDMA
2/3/2023
Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of PCT patent applications covering novel prodrugs of DMT, 5-MeO-DMT, and MDMA.
-
New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and psychological indications.
-
Terran Biosciences announces licensing deal with Sanofi for two late-stage CNS pipeline assets
4/21/2022
Terran Biosciences, Inc. has entered into an agreement with Sanofi S.A. ("Sanofi") for worldwide exclusive rights to develop and commercialize two late-stage CNS pipeline assets.
-
Role of Biomarkers In Neurodegenerative Diseases
4/13/2022
With the increase in life expectancy in several countries, the prevalence of neurodegenerative diseases has considerable increased.
-
Terran Biosciences and Blumentech S.L. announce the acquisition of a patent portfolio covering the groundbreaking discoveries of prominent psychedelics researcher Dr. Jordi Riba
4/13/2022
Terran Biosciences ("Terran"), has entered into an agreement with Blumentech S.L. ("Blumentech") to acquire Blumentech's full patent portfolio and accompanying data, which includes multiple groundbreaking discoveries by the late Dr. Jordi Riba Serrano, a renown ethno-pharmacologist and pioneer of psychedelics research.
-
Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform
3/16/2022
Terran Biosciences, Inc. ("Terran"), has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
-
Terran Biosciences announces acquisition of a portfolio of novel CNS therapeutics from Concert Pharmaceuticals
3/11/2022
Terran Biosciences ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has entered into an agreement with Concert Pharmaceuticals ("Concert") to acquire a portfolio of Concert's CNS therapeutics and accompanying intellectual property.